C ardiovascular disease is the number 1 cause of death among women and results in 1 in 3 deaths each year.
C ardiovascular disease is the number 1 cause of death among women and results in 1 in 3 deaths each year. 1 Typically, before menopause, men have a higher prevalence of hypertension than women. 2 However, after menopause, this relationship is reversed with the prevalence of hypertension greater in postmenopausal women compared with premenopausal women. 3 Standard treatment options for postmenopausal hypertension are not clear. 4 According to results derived from the Women's Health Initiative, diuretics and calcium channel blockers were the most commonly prescribed therapy for postmenopausal hypertension. 5 Yet, two-thirds of menopausal women, who are most at risk for stroke and cardiovascular events, do not have their hypertension adequately controlled while taking medications; thus, leading to the conclusion that more aggressive therapies are needed to prevent the progression of hypertension in this subset of the population. 4 The cause of hypertension in women is multifactorial and includes activation of the reninangiotensin system, 6 the endothelin system, 7 and the sympathetic nervous system. 8 Another suggested contributor to the cause of postmenopausal hypertension is an imbalance in the hormonal milieu, 9 in particular, a decrease in estrogens relative to androgens. Yet, further investigation into the role of sex hormones in the cause of the increased prevalence of hypertension that develops in women in later life is warranted.
Birth weight is inversely associated with blood pressure (BP) in men and women. 10 This relationship is amplified with age 11 with low birth weight (LBW) women twice as likely to become hypertensive by the age of 60 years compared with their normal birth weight counterparts. 12 Yet, the mechanisms that contribute to the greater prevalence of hypertension in LBW women in later life is unknown. Experimental models of developmental origins report that males are hypertensive during young adulthood, whereas female are protected in early life. [13] [14] [15] In addition to hypertension, LBW in women is also associated with an increase in adiposity 10 and an earlier age at menopause 16 ; both of which are risk factors for hypertension. Our laboratory uses a model of developmental origins induced by placental insufficiency in the rat to study the inverse relationship between BP and birth weight. 13 Female intrauterine growth-restricted offspring are normotensive during young adulthood. However, at 12 months of age, BP is elevated in female growth-restricted offspring compared with control indicating that female rats born growth-restricted are no longer protected at 12 months of age. 17 In our experimental model, female growth-restricted offspring enter into a state of persistent estrous by 12 months of age, or 6 months before female control, indicative of early reproductive senescence. 18 Previous studies from our laboratory also indicate that circulating levels of testosterone are elevated in female growth-restricted offspring in association with the increase in BP; estradiol levels do not differ 18 implicating a shift towards a prevalence of testosterone. Blockade of the AR (androgen receptor) abolishes the increase in BP in female growthrestricted offspring at 12 months of age. 19 Androgen blockade also abolishes the increase in circulating testosterone. 19 Thus, the aim of this study was to test the hypothesis that chronic supplementation of 17β-estradiol (E2), resulting in a shift to higher circulating levels of estradiol would be protective against increased BP in female growth-restricted offspring in later life.
Materials and Methods
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Animals
All experimental procedures were conducted in accordance with National Institutes of Health guidelines. All protocols were approved by the Animal Care and Use Committee at the University of Mississippi Medical Center. Rats were housed in a temperature-controlled room (23°C) with a 12:12-hour light-dark cycle with food and water available ad libitum. Timed-pregnant Sprague Dawley rats were purchased from Envigo, Inc (Indianapolis, IN). At day 14 of gestation, pregnant rats were randomly selected to undergo either the reduced uterine perfusion or a sham procedure as described in the online-only Data Supplement. All pregnant rats were allowed to deliver at term with birth weights recorded within 12 hours of delivery. Pups of control and reduced uterine perfusion litters were culled to 4 female and 4 male pups per dam at 48 hours after birth to allow equal nutrition access for all offspring while maintaining a 1 to 1 sex ratio per litter. Only female control offspring from sham-operated dams and female growthrestricted offspring from reduced uterine perfusion dams were used in this study. Final groups included offspring from 18 sham-operated and 16 reduced uterine perfusion pressure pregnant rats. To ensure diversity and that programmed influences were not representative of a litter effect, 1 to 2 pups per sex per litter were used per study parameter. All animals undergoing surgical procedures were anesthetized using 2% to 5% isoflurane by inhalation. Offspring were randomly selected for the different study groups. Systemic and molecular experimental end points for the 17β-estradiol supplementation study and the selective GPER (G-protein coupled estrogen receptor 1) agonist, G1, study were performed in separate cohort of animals with measured BP measured at 13.5 and 14.5 months of age, respectively, followed by the harvest of kidney cortex, kidney medulla, visceral fat, uterine weight, serum, and plasma. Vaginal cytology was performed in an additional cohort. A more detailed Methods section is available in the onlineonly Data Supplement.
Supplementation With 17β-Estradiol
17β-estradiol valerate mini pellets (1.5 mg for 60-day release, E2-treated) or placebo pellet (placebo-treated) from Innovative
Research of America of Sarasota, FL, were inserted subcutaneously in the dorsum of the neck for continuous release of hormone at a dose chosen to mimic the normal E2 levels observed in adult Sprague Dawley female control animals (25±2 ng/dL).
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Administration of the Selective GPER Agonist, G1
The GPER agonist, G1 (400 µg/([kg·day], Cayman Chemical, Ann Arbor, MI) dissolved in dimethyl sulfoxide (DMSO) and saline or vehicle were administered via osmotic pumps (model 2ML2; Alzet: Cupertino, CA) implanted at the dorsum of the neck for 2 weeks beginning at 14 months of age.
Statistics
GraphPad PRISM version 4 (Graph Pad Software, San Diego, CA) was used for all statistical analysis. Comparisons among groups were performed by 2-way ANOVA. Unpaired Student t test was used for comparison of birth weight, baseline body weight, and litter before cull analysis. The level of significance was set at P<0.05. All results are presented as mean±SEM.
Results
17β-Estradiol Study
Mean Arterial Pressure
Mean arterial pressure (MAP) was significantly increased in placebo-treated growth-restricted offspring relative to placebo-treated control at 13.5 months of age ( Figure 1 ), a finding previously reported by our lab. 17 MAP was significantly reduced in E2-treated growth-restricted relative to placebo-treated growth-restricted ( Figure 1 ). Importantly, MAP in E2-treated growth-restricted offspring was not significantly elevated compared with placebo-treated control. MAP did not differ between placebo-treated and E2-treated control groups.
Uterine Weight, Serum, and Plasma Estradiol Uterine weight, a crude marker of circulating E2, did not differ in control offspring regardless of treatment group; yet, uterine weight was significantly increased in E2-treated growth-restricted offspring relative to placebo-treated control and placebo-treated growth-restricted (Figure 2A ). Circulating E2 levels did not differ between control and growth-restricted offspring regardless of treatment group ( Figure 2B and 2C). However, circulating E2 was significantly increased in E2-treated groups compared with placebo groups ( Figure 2B and 2C).
Renal mRNA Expression
Cortical ER-α (estrogen receptor alpha) mRNA expression did not differ in placebo-treated growth-restricted versus placebo-treated control offspring. However, cortical ER-α mRNA expression was significantly increased in E2-treated growth-restricted offspring relative to all other groups ( Figure 3A) . Medullary ER-α mRNA expression was significantly increased in E2-treated control and growth-restricted offspring compared with placebo-treated groups ( Figure 3B ). There was no significant difference in cortical ER-β (estrogen receptor beta) mRNA expression among groups regardless of birth weight or treatment ( Figure 3C ). Medullary ER-β mRNA expression was significantly increased in E2-treated growth-restricted relative to placebo-treated growth-restricted and E2-treated control ( Figure 3D ). Cortical mRNA expression of GPER was decreased in both control and growthrestricted E2-treated groups relative to placebo-treated groups ( Figure 3E ), whereas medullary GPER mRNA expression was decreased in growth-restricted offspring relative to control counterpart ( Figure 3F ).
Cortical and medullary AT1aR (angiotensin type 1a receptor) mRNA expression did not differ between placebotreated and E2-treated offspring ( Figures 4A and 4B ). Cortical AT1bR (angiotensin type 1b receptor) mRNA expression also did not differ between groups ( Figure 4C ). However, medullary AT1bR ( Figure 4D ) mRNA expression was significantly increased in E2-treated growth-restricted relative to all other groups. Cortical and medullary AR mRNA expression was significantly elevated in placebo-treated control in comparison to placebo-treated growth-restricted offspring ( Figure 4E and 4F). After E2 supplementation, cortical AR mRNA expression was decreased in E2-treated controls but increased in E2-treated growth-restricted rats relative to their placebotreated counterparts ( Figure 4E ). However, in the medulla, AR mRNA expression was increased in E2-treated controls relative to their placebo-treated counterpart ( Figure 4F ).
G1 Agonist Study
Mean Arterial Pressure MAP was significantly elevated in vehicle-treated growthrestricted relative to vehicle-treated control ( Figure 5 ). However, MAP was significantly decreased in G1-treated growth-restricted relative to vehicle-treated growth-restricted offspring and did not differ relative to placebo-treated female control ( Figure 5 ).
Renal mRNA Expression
AT1aR cortical mRNA expression was significantly decreased in G1-treated growth-restricted compared with vehicletreated growth-restricted ( Figure 6A ). Medullary AT1aR mRNA expression did not differ regardless of birth weight or treatment ( Figure 6B ). Cortical and medullary mRNA expression of AT1bR was significantly elevated in vehicletreated growth-restricted relative to vehicle-treated control ( Figure 6C and 6D ). Cortical and medullary AT1bR mRNA expression was decreased in G1-treated growth-restricted relative to vehicle-treated growth-restricted ( Figure 6C and 6D) . Cortical AR mRNA expression was decreased in G1-treated growth-restricted relative to vehicle-treated growth-restricted ( Figure 6E ). In addition, medullary AR mRNA expression was significantly increased in vehicle-treated growth-restricted compared with vehicle-treated control ( Figure 6F ). However, medullary AR mRNA expression was decreased in G1-treated growth-restricted relative to vehicle-treated growth-restricted. However, AR mRNA expression was increased in G1-treated controls compared with their vehicle-treated counterparts ( Figure 6F ). ) , and GPER (G-protein coupled estrogen receptor 1) mRNA expression in the kidney cortex and medulla from placebo-treated and E2-treated control and intrauterine growth-restricted (IUGR) rats at 13.5 mo of age. Cortical ER-α mRNA expression (A), medullary ER-α mRNA expression (B), cortical ER-β mRNA expression (C), medullary ER-β mRNA expression (D), cortical GPER mRNA expression (E), and medullary GPER mRNA expression (F) in placebo-treated and E2-treated control and IUGR, (n=5-6/group). Data are expressed as fold changes relative to the mean expression level of the placebo-treated control, which is arbitrarily defined as 1. *P<0.05 vs all groups; †P<0.05 vs placebotreated groups; ‡P<0.05 vs E2-treated control; §P<0.05 vs placebo-treated IUGR. P<0.05 denotes significance. Data values represent mean±SEM.
Discussion
The main findings from this study demonstrated that chronic E2 supplementation abolished the increase in BP that naturally develops around 1 year of age in intact, female growthrestricted offspring. Administration of the GPER agonist, G1, also abolished the age-related increase in BP in female growth-restricted offspring. Additionally, renal AT1aR and AT1bR mRNA expression were not elevated in G1-treated growth-restricted offspring relative to placebo-treated counterparts. Collectively, these data suggest that administration of E2 was protective against increased BP in female growthrestricted offspring via a mechanism that may involve activation of GPER and its actions on the renin-angiotensin system (RAS).
We previously reported that BP is not elevated in female growth-restricted offspring in young adulthood 12 but is elevated in female growth-restricted offspring at 12 months of age in association with an increase in circulating testosterone but no change in circulating estradiol. 18, 19 This shift in the hormonal milieu in female growth-restricted offspring at 12 months of age is associated with cessation of estrous cyclicity 6 months before female control, indicative of accelerated reproductive senescence. 18 Early onset reproductive senescence [21] [22] [23] and the development of increased BP 24, 25 in female offspring is also reported in other experimental models of developmental origins. Collectively, our studies, in addition to others, suggest that adverse fetal exposures may influence the age at reproductive senescence and program an increased susceptibility to hypertension in female offspring in later life. Therefore, the goal of this project was to determine the importance of the hormonal imbalance in the pathogenesis of elevated BP that develops in intact female growth-restricted offspring by 1 year of age.
Hypertension in women after menopause is associated with a decrease in estrogens and a shift in the testosterone to estradiol ratio. 9 Numerous experimental models of hypertension indicate a protective effect by E2 on BP in ovarian deficient rats in young adulthood [26] [27] [28] or middle age (12 months or older). 29, 30 In the current study, chronic E2 supplementation, initiated at 12 months of age in intact female growth-restricted offspring, resulted in a decrease in BP associated with an increase in uterine weight, a crude marker of circulating estradiol. These data suggest that a shift in the hormonal milieu to a sustained increase in circulating estradiol contributed to the decrease in BP. However, the benefit of hormone replacement in postmenopausal women is highly controversial. The timing hypothesis, as discussed in the review by Miller and Harman, 31 suggests that administration of hormone replacement within a time span of ≤10 years from the onset of menopause may be beneficial against cardiovascular risk. Thus, in accordance with the timing hypothesis, E2 supplementation in our study may have been administered within a timeframe that was beneficial.
Experimental studies indicate that the beneficial effect of ovarian hormones may involve a role for the RAS, which may differ with age. 32 We previously reported that an increase in BP and circulating testosterone in female growth-restricted offspring in later life is associated with an increase in medullary AT1aR and AT1bR mRNA expression. 19 This study by Dasinger et al 19 also demonstrated that BP and medullary mRNA expression of AT1aR and AT1bR are decreased in female growth-restricted offspring chronically treated with flutamide, an AR antagonist, relative to vehicle-treated counterparts. Moreover, medullary ACE2 (angiotensin-converting enzyme 2) mRNA expression was increased in flutamidetreated female growth-restricted offspring. 19 Collectively, these data suggested that the protective effect of chronic AR blockade in female growth-restricted offspring involved a shift in the RAS from the classic vasoconstrictive to the counter-regulatory arm. We also previously reported that BP in female growth-restricted offspring in later life is abolished by the ACE inhibitor, enalapril, indicating a key role for the RAS in the pathogenesis of increased BP that develops by 12 months of age in female growth-restricted offspring. 19 In the current study, chronic supplementation with E2 was not associated with a decrease in renal mRNA expression of the AT1 receptors; yet, medullary mRNA expression of ACE2 was increased in E2-treated growth-restricted relative to placebotreated counterparts.
The biological actions of E2 involve its receptors ER-α, ER-β, GPER. 33 E2's protective role on the cardiovascular system includes increased angiogenesis, increased vasodilation of the vasculature, reduced oxidative stress, and reduced fibrosis.
34 E2 may also contribute to BP regulation via its actions on the RAS. 35 However, the exact mechanisms by which E2 mediates these effects are not well understood. Recent studies report a vascular 36 and centrally mediated role 37 for ER-β in protection from hypertension. Yet, ER-α and GPER mRNA expression are the predominant receptors found in the kidney of female Sprague Dawley rats. 38 Lindsey et al 39 report that activation of GPER, via G1, lowers BP in female mRen2.Lewis rats that develop ovariectomy-induced hypertension. Aortic AT1 receptor mRNA expression is also reduced in female ovariectomized, G1-treated mRen2.Lewis rats, 39 implicating a role for GPER in E2-mediated effects on the RAS. Although our initial hypothesis was to determine the beneficial effect of chronic E2 supplementation on BP, subsequently, we wanted to test the hypothesis that the membrane-bound receptor GPER contributes to the regulation of BP in female growth-restricted offspring through a mechanism that may also involve the renal RAS. Although BP was decreased in G1-treated female growth-restricted offspring, uterine weight did not differ between vehicle and G1-treated offspring indicating that chronic treatment with G1 did not have an effect on ER-α or ER-β activation. 40, 41 However, renal AT1aR and AT1bR mRNA expression were not elevated in G1-treated growth-restricted offspring relative to vehicle-treated counterparts suggesting that GPER's actions on BP may be mediated by suppression of the renal RAS. Renal AR mRNA expression was also decreased in G1-treated growth-restricted offspring. Vaucher et al 42 report Figure 5 . Effect of a GPER (G-protein coupled estrogen receptor 1) agonist (G1) on mean arterial pressure (MAP) at 14. that activation of GPER, via G1, results in a decrease in testosterone production in Leydig cells of adult rat and human testis. Collectively, these findings suggest a role for GPER activation on BP regulation in female growth-restricted offspring that is mediated via suppression of the angiotensin receptordependent vasoconstrictor arm of the renal RAS that may also involve suppression of androgen-dependent mechanisms.
Perspectives
Previous studies from our laboratory suggest that a shift in the hormonal milieu towards androgen excess precipitates the development of hypertension in female growthrestricted offspring in later life. This study demonstrated that chronic E2 supplementation, resulting in a sustained increase in circulating E2, abolished the increase in BP that spontaneously develops in female growth-restricted offspring by 12 months of age. Whether the greater prevalence of hypertension in LBW women in later life 12 is positively associated with testosterone and whether hormone replacement in LBW women would be beneficial is unknown. Yet, this study provides insight into 1 potential mechanism that may contribute to the greater prevalence of increased cardiovascular risk that develops in LBW women as they age, the importance of a shift in the hormonal milieu, and also highlights that timing of hormone supplementation may be most beneficial if administered in close proximity to reproductive senescence.
